DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...

Dexcom received FDA clearance for its first over-the-counter continuous glucose monitor, called Stelo. The device is intended for people with Type 2 diabetes who do not take insulin. · MedTech Dive · ...

Every day there are new posts in a Facebook group — 89.5 thousand members strong — dedicated to Dexcom G7 issues and complaints. From inaccurate CGM readings and sensor failures to frustrating ...

The CONNECT trial, presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans, found that 82% of adults with type 2 diabetes who used a Dexcom G7 improved their blood ...

FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...

Dexcom is transforming its Stelo CGM into a whole-family wellness device, securing FDA clearance for pediatric use and debuting new AI tools.

Compare the best Samsung Watch CGM apps and Wear OS tools for blood sugar readings, including Dexcom G6, Gluroo, and xDrip+.

DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of the Dexcom G7 continuous glucose monitoring (CGM) system significantly ...

Continuous glucose monitors have become popular among those who need to track their glucose levels because they're painless ...